Neomycin and plasma lipoproteins in type II hyperlipoproteinemia

Jeffrey M. Hoeg, Ernst J. Schaefer, Carol A. Romano, Ernestina Bou, Anita M. Pikus, Loren A. Zech, Kent R. Bailey, Richard E. Gregg, Peter W.F. Wilson, Dennis L. Sprecher, Alison M. Grimes, Nancy G. Sebring, Elaine J. Ayres, Claus E. Jahn, H. B. Brewer

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


Neomycin, a nonabsorbable aminoglycoside antibiotic, has been shown to exert a hypocholesterolemic effect in man. In a 9-mo, double-blind, randomized, crossover, placebo-controlled clinical trial, the effect of neomycin, 2 gm/day, on plasma lipoproteins, as well as its safey, was described in 20 subjects with type II hyperlipoproteinemia. A 15% (50 mg%) decline in plasma cholesterol concentration was observed with neomycin. Most of this effect resulted from a 41 mg% (16%) decrease in low-density lipoprotein cholesterol concentration. No significant or consistent effect on the concentration of high-density lipoprotein cholesterol was observed. Monthly audiologic and renal evaluation disclosed no oto- or nephrotoxicity. Neomycin treatment in patients with type 11 hype rlipoproteinemia is an inexpensive and effective means of lowering the concentration of low-density lipoproteins and is free of significant side effects over a 3-mo period.

Original languageEnglish (US)
Pages (from-to)555-565
Number of pages11
JournalClinical pharmacology and therapeutics
Issue number4
StatePublished - Oct 1984

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Neomycin and plasma lipoproteins in type II hyperlipoproteinemia'. Together they form a unique fingerprint.

Cite this